Artelo Biosciences, Inc. ARTLW
At closeNov 25, 2025, 4:00 PM EST
- Market cap
- 13.07K
- EPS (ttm)
- -1.43
- Shares out
- 2.33M
- Volume
- 29.40K
- Open
- 0.0056
- Previous close
- 0.0056
- Day's range
- 0.0056 – 0.0056
- 52-week range
- 0.0056 – 0.0056
- Beta
- 1.25
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.29M
- Total cash
- 7.61M
- Total debt
- 127.00K
- Return on equity
- -70.68%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
About Artelo Biosciences, Inc.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- artelobio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ARTLW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.00% | 162 | 0 | Mar 30, 2024 |